Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adults with Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome (AML19): a randomised, controlled, open label Phase III trial

Trial Profile

Adults with Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome (AML19): a randomised, controlled, open label Phase III trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine/daunorubicin (Primary) ; Ganetespib (Primary) ; Gemtuzumab ozogamicin (Primary) ; Midostaurin (Primary) ; Cytarabine; Fludarabine; Granulocyte colony-stimulating factors; Idarubicin
  • Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms AML-19
  • Most Recent Events

    • 12 Dec 2023 Results assessing comprehensive genotyping and molecular MRD assessment in two consecutive prospective randomised studies (NCRI AML17 (2009-2014) and AML19 (2015-2020)) presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 10 Dec 2023 According to an American Society of Hematology media release, data from this study are being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition highlight, by Jad Othman.
    • 10 Dec 2023 Results presented in an American Society of Hematology media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top